{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T22:36:21Z","timestamp":1772490981856,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jfo.2021.02.015","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T07:39:39Z","timestamp":1627285179000},"page":"1216-1222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quality of timolol eye drops marketed in Kinshasa, Democratic Republic of the Congo"],"prefix":"10.1016","volume":"44","author":[{"given":"N.N.","family":"Kabedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.K.","family":"Kalangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.M.","family":"Kimbeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-5885","authenticated-orcid":false,"given":"J.C.","family":"Mwanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2021.02.015_bib0200","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/434132a","article-title":"Counterfeit pharmaceuticals: murder by medicine","volume":"434","author":"Aldhous","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jfo.2021.02.015_bib0205","first-page":"128","article-title":"Health risks related to illegal and on-line sale of drugs and food supplements: results of a survey on marketed products in Italy from 2011 to 2013","volume":"52","author":"Gaudiano","year":"2016","journal-title":"Ann Ist Super Sanita"},{"key":"10.1016\/j.jfo.2021.02.015_bib0210","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1520\/JFS16186J","article-title":"Comparison of antiepileptic drug levels in different cases of sudden death","volume":"43","author":"George","year":"1998","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.jfo.2021.02.015_bib0215","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.15585\/mmwr.mm6450a2","article-title":"Fatal bacterial meningitis possibly associated with substandard ceftriaxone\u00a0\u2013\u00a0Uganda, 2013","volume":"64","author":"Nickerson","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jfo.2021.02.015_bib0220","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S1474-4422(15)00255-0","article-title":"Counterfeit antiepileptic drugs threaten community services in Guinea-Bissau and Nigeria","volume":"14","author":"Otte","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfo.2021.02.015_bib0225","doi-asserted-by":"crossref","first-page":"420","DOI":"10.15585\/mmwr.mm6516e1","article-title":"Counterfeit norco poisoning outbreak\u00a0\u2013\u00a0San Francisco Bay area, California, March 25\u2013April 5, 2016","volume":"65","author":"Vo","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jfo.2021.02.015_bib0230","first-page":"216","article-title":"The health and economic effects of counterfeit drugs","volume":"7","author":"Blackstone","year":"2014","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jfo.2021.02.015_bib0235","doi-asserted-by":"crossref","first-page":"e021825","DOI":"10.1136\/bmjopen-2018-021825","article-title":"Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority","volume":"8","author":"Mori","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jfo.2021.02.015_bib0240","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2710.2007.00797.x","article-title":"Quality evaluation of chloroquine, quinine, sulfadoxine-pyrimethamine and proguanil formulations sold on the market in East Congo DR","volume":"32","author":"Atemnkeng","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jfo.2021.02.015_bib0245","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/HJH.0000000000001560","article-title":"Substandard drugs among five common antihypertensive generic medications: an analysis from 10 African countries","volume":"36","author":"Macquart de Terline","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfo.2021.02.015_bib0250","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpba.2013.06.036","article-title":"Application of an innovative design space optimization strategy to the development of LC methods for the simultaneous screening of antibiotics to combat poor quality medicines","volume":"85","author":"Mbinze","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.jfo.2021.02.015_bib0255","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.chroma.2012.09.038","article-title":"Application of an innovative design space optimization strategy to the development of liquid chromatographic methods to combat potentially counterfeit nonsteroidal anti-inflammatory drugs","volume":"1263","author":"Mbinze","year":"2012","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.jfo.2021.02.015_bib0260","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12936-016-1659-x","article-title":"The malaria testing and treatment market in Kinshasa, Democratic Republic of the Congo, 2013","volume":"16","author":"Mpanya","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.jfo.2021.02.015_bib0265","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/dta.2420","article-title":"Quality of the antimalarial medicine artemether \u2013 lumefantrine in 8 cities of the Democratic Republic of the Congo","volume":"10","author":"Mufusama","year":"2018","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.jfo.2021.02.015_bib0270","first-page":"282","article-title":"Preliminary survey of counterfeiting of albendazole and metronoidazole marketed in Lubumbashi","volume":"8","author":"Mwamba","year":"2010","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.jfo.2021.02.015_bib0275","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/S2214-109X(16)30287-X","article-title":"An epidemic of dystonic reactions in central Africa","volume":"5","author":"Peyraud","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jfo.2021.02.015_bib0280","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4269\/ajtmh.17-0732","article-title":"The quality of medicines used in children and supplied by private pharmaceutical wholesalers in Kinshasa, Democratic Republic of Congo: a prospective survey","volume":"98","author":"Schiavetti","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jfo.2021.02.015_bib0285","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4236\/pp.2016.75024","article-title":"Preliminary study on counterfeiting of artemether and artesunate marketed in Lubumbashi","volume":"7","author":"Tshilumba","year":"2016","journal-title":"Pharmacol Pharm"},{"key":"10.1016\/j.jfo.2021.02.015_bib0290","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jfo.2021.02.015_bib0295","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/archopht.1994.01090180121046","article-title":"The Barbados Eye Study. Prevalence of open-angle glaucoma","volume":"112","author":"Leske","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2021.02.015_bib0300","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.1991.03470030069026","article-title":"Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey","volume":"266","author":"Tielsch","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.jfo.2021.02.015_bib0305","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0161-6420(98)97012-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients","volume":"105","author":"AGIS","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2021.02.015_bib0310","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/IJG.0b013e318189158c","article-title":"Glaucoma in Africa: size of the problem and possible solutions","volume":"18","author":"Cook","year":"2009","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jfo.2021.02.015_bib0315","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00004397-200404420-00006","article-title":"Primary open-angle glaucoma in African Americans","volume":"44","author":"Girkin","year":"2004","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.jfo.2021.02.015_bib0320","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJM199111143252004","article-title":"Racial differences in the cause-specific prevalence of blindness in east Baltimore","volume":"325","author":"Sommer","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2021.02.015_bib0325","series-title":"Guidelines for the development of measures to combat counterfeit drugs","first-page":"1","author":"World Health Organization","year":"1999"},{"key":"10.1016\/j.jfo.2021.02.015_bib0330","series-title":"European pharmacopoeia","author":"European D for the Quality of Medicines","year":"2006"},{"key":"10.1016\/j.jfo.2021.02.015_bib0335","series-title":"British pharmacopoeia","author":"British P Commission","year":"2004"},{"key":"10.1016\/j.jfo.2021.02.015_bib0340","series-title":"The official compendium standards","author":"USP","year":"2016"},{"key":"10.1016\/j.jfo.2021.02.015_bib0345","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1365-3156.2008.02106.x","article-title":"Substandard medicines in resource-poor settings: a problem that can no longer be ignored","volume":"13","author":"Caudron","year":"2008","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jfo.2021.02.015_bib0350","first-page":"205","article-title":"Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy","volume":"5","author":"Nsimba","year":"2008","journal-title":"East Afr J Public Health"},{"key":"10.1016\/j.jfo.2021.02.015_bib0355","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1046\/j.1365-3156.1997.d01-403.x","article-title":"Assessment of the incidence of substandard drugs in developing countries","volume":"2","author":"Shakoor","year":"1997","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jfo.2021.02.015_bib0360","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(01)06516-3","article-title":"Substandard drugs","volume":"358","author":"Issack","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jfo.2021.02.015_bib0365","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ophtha.2012.07.083","article-title":"Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China","volume":"120","author":"Wang","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2021.02.015_bib0370","series-title":"HSA alerts public to counterfeit \u201cEye Mo Regular\u201d (7.5 mL) and \u201cEye Mo Moist\u201d eye drops (7.5 mL) sold locally","author":"HSA","year":"2016"},{"key":"10.1016\/j.jfo.2021.02.015_bib0375","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archopht.1981.03930010303017","article-title":"Normal human tear pH by direct measurement","volume":"99","author":"Abelson","year":"1981","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2021.02.015_bib0380","series-title":"2018 Forbes Media LLC","author":"Harper M Bad medicine","year":"2005"},{"key":"10.1016\/j.jfo.2021.02.015_bib0385","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/bjo.2006.106518","article-title":"To what extent does a lack of refrigeration of generic chloramphenicol eye drops used in India decrease their purity and what are the implications for Europe?","volume":"92","author":"Aboshiha","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.02.015_bib0390","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00061198-200112000-00008","article-title":"Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization","volume":"10","author":"Novack","year":"2001","journal-title":"J Glaucoma"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551221003739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551221003739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:17:22Z","timestamp":1759259842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551221003739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0181551221003739"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2021.02.015","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of timolol eye drops marketed in Kinshasa, Democratic Republic of the Congo","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2021.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}